Skip to content

Advertisement

  • Short Report
  • Open Access

Antimicrobial susceptibility pattern of Shigella spp. isolated from children under 5 years of age attending tertiary care hospitals, Nepal along with first finding of ESBL-production

  • 1Email authorView ORCID ID profile,
  • 2,
  • 2,
  • 2,
  • 2,
  • 2,
  • 2,
  • 1,
  • 3 and
  • 2
BMC Research Notes201710:192

https://doi.org/10.1186/s13104-017-2512-1

©  The Author(s) 2017

  • Received: 16 July 2016
  • Accepted: 24 May 2017
  • Published:

Abstract

Background

Shigella is an important cause of bacterial gastroenteritis in resource-poor countries. The treatment of shigellosis mostly requires antibiotics. However, the increase of multidrug resistance along with emergence of extended-spectrum β-lactamase and ciprofloxacin resistance among Shigella spp. has challenged the situation. This study was conducted to determine the distribution of species and antibiotic susceptibility pattern of Shigella species isolated from stool specimen among children less than 5 years of age in Nepal.

Results

Out of total 717 stool samples collected, 15 cases of Shigella spp. was isolated which includes 12 S. flexneri and 3 S. sonnei. Multidrug resistance was found among 13(86%) of the isolates. One of the isolates of S. flexneri was found to be ESBL-producer with MIC >256 mg/L for cefixime.

Conclusion

The high occurrence of multidrug resistance among Shigella spp. along with a case of ESBL-production for the first time in Nepal alarms the concerns about dissemination of the resistant isolates. So, systemic monitoring of the antimicrobial susceptibility pattern of Shigella spp. is becoming crucial to guide therapy.

Keywords

  • Shigella
  • Antibiotic resistance
  • ESBL
  • Nepal

Background

Shigella is an important cause of bacterial gastroenteritis in resource-poor countries where children less than 5 years of age are major affected population [1]. Antimicrobial agents can lessen the severity of disease and potentially prevent lethal complications; however, sulphonamide–trimethoprim, tetracycline, ampicillin are no longer recommended for empirical treatment because of the high chances of resistance [2]. In addition, the increase of multidrug resistance along with emergence of extended-spectrum β-lactamase (ESBL) and/or ciprofloxacin resistance among Shigella spp. has made the situation challenging [3–6].

In current scenario, majority of the members of the family Enterobacteriaceae were shown to produce ESBL including Shigella. Third-generation cephalosporin-resistant S. flexneri isolate was first reported from a stool sample of a 16-month old child in Paris in 1995 [7]. In the recent years, various ESBL-producing Shigella were also reported from Korea [8], Argentina [9], Vietnam [10], Turkey [11] and India [12].

The free access of antibiotics from pharmacy without prescription, lack of antibiotic policy and dedicated laboratory for susceptibility testing and surveillance is leading to distressing public health threat of antibiotic resistance in Nepal. The prevalence of ESBL in Nepal is found to be 13–24% in different clinical isolates, predominantly Escherichia coli [13–15]. ESBLs are beta-lactamases capable of conferring bacterial resistance to the penicillins, first-, second-, and third-generation cephalosporins, and aztreonam except the cephamycins or carbapenems with various genotypes such as CTX-M, TEM, SHV, OXA [16]. Though extended-spectrum β-lactamase production in Shigella has not been reported from Nepal, the transfer of ESBL genes to Shigella spp. is possible through mobile genetic elements and plasmids [17].

This study was conducted to determine the distribution of species and antibiotic susceptibility pattern of Shigella species isolated from stool specimen of children less than 5 years of age in Nepal.

Methods

Single stool samples were collected from the children less than 5 years of age attending two referral hospitals in Kathmandu, Tribhuvan University Teaching Hospital (TUTH) and Kanti Childrens’ Hospital, from January to December 2014, with acute diarrheal illness. These hospitals are large centers in the country taking care of around 1500 acute diarrheal cases in observation ward and OPD services in a year. In the study, children admitted in hospital for longer than 3 days and/or in antibiotic use were followed as exclusion criteria. The laboratory investigation was performed following the technical guidelines of American Society for Microbiology at Department of Microbiology, TUTH [18]. The direct inoculation of stool sample was done in Xylose Lysine Deoxycholate Agar (XLD) while 6 h enriched Gram Negative broth were cultured into MacConkey agar (MA) and incubated at 37 °C for 24 h. Non lactose fermenting pale colonies from MA or pink colonies from XLD were tested for indole production, citrate utilization, urease production, lysine decarboxylation, acid and gas production with sugar utilization and motility. Presumptive Shigella isolates were serotyped based on serological slide agglutination, using the polyvalent antisera A–D (Shigella Antisera, Denka Seiken, Japan). The antibiotic sensitivity tests of Shigella spp. were performed using following antibiotic disks (Hi-media, Mumbai, India): amoxicillin (10 μg), nalidixic acid (10 μg), cotrimoxazole (1.25 μg/23.75 μg), ciprofloxacin (5 μg), azithromycin [19], tetracycline (10 μg), cefixime (5 μg), ceftriaxone (30 μg), ceftazidime (30 μg), ampicillin/sulbactam (10 μg/10 μg) and interpreted as recommended by CLSI [20]. The isolates having resistant zone diameters against cefixime, ceftriaxone or ceftazidime were further tested for Minimum Inhibitory Concentration (MIC) of cefixime by agar dilution and ESBL was confirmed by phenotypic disk diffusion methods, double disk synergy test and combination disk method, depicted in Fig. 1 as described by CLSI [20]. For combination disk method, ≥5 mm increase in a zone diameter for either third generation cephalsporin tested in combination with clavulanic acid versus its zone when tested alone was used as interpretative criteria to confirm an ESBL-production.
Fig. 1
Fig. 1

Extended spectrum β-lactamase (ESBL) detection by combination disk method

Results

In the study, total fifteen Shigella isolates were identified (2.1% of total cases). Shigella flexneri was isolated from 12 cases whereas Shigella sonnei was isolated from three cases.

The antibiotic sensitivity pattern of Shigella spp. depicts that 33% of the isolates were sensitive to amoxicillin, cotrimoxazole and ciprofloxacin and one isolate is resistant to third generation cephalosporin, which is presented in Table 1.
Table 1

Antimicrobial susceptibility pattern of Shigella

Antibiotics

Shigella flexneri (n = 12)

Shigella sonnei (n = 3)

Sensitive

Resistant

Sensitive

Resistant

Amoxycillin

2

10

3

0

Nalidixic acid

3

9

0

3

Cotrimoxazole

5

7

0

3

Ciprofloxacin

5

7

0

3

Tetracycline

4

8

2

1

Azithromycin

8

4

3

0

Cefixime

11

1

3

0

Ceftazidime

11

1

3

0

Ceftriaxone

11

1

3

0

Ampicillin sulbactam

4

8

3

0

MDR pattern of Shigella spp.

Out of total 15 isolates, 13 isolates were found to be multidrug resistant representing 86% of the total isolates. The MDR pattern of Shigella spp. is presented in Table 2.
Table 2

MDR pattern of Shigella spp.

MDR pattern

Number of isolates

Amoxycillin + nalidixic acid + cotrimoxazole

3

Amoxycillin + nalidixic acid + ciprofloxacin

5

Amoxycillin + cotrimoxazole + ciprofloxacin

3

Nalidixic acid + cotrimoxazole + ciprofloxacin

7

MIC of cefixime

Out of 15 isolates, 14 isolates had cefixime MIC ≤0.5 mg/L and one of the isolate had >256 mg/L.

ESBL-production

One of the S. flexneri isolate was found to be ESBL-producer, in fact a multidrug resistant, being resistant to ciprofloxacin, cotrimoxazole and third generation cephalosporin.

Discussion

The study was conducted from January to December 2014 among children less than 5 years suffering from acute diarrhea, attending inpatient and outpatient department of Tribhuvan University Teaching Hospital and Kanti Children’s Hospital. In the study, Shigella spp. were isolated from 2.1% of total cases. Shigella flexneri was isolated from 12 cases whereas S. sonnei was isolated from three cases. Similar to this study, Shah et al. reported that Shigella species accounted for 2.24% of total cases and S. flexneri was the only isolated species [21]. In accordance to the present study, S. flexneri has been found to be major cause of shigellosis in developing countries [1]. Zhang et al. reported S. flexneri among 78.7% cases from China [6]. However, in a study conducted at Eastern Nepal by Bhattacharya et al. [22] the predominant isolate was Shigella dysenteriae (73.7%), followed by S. flexneri (23%) and Shigella boydii (4%).

In studies made in Nepal, from 1999 to 2002 S. flexneri accounted for 38% and was behind S. dysenteriae (42%) while in study made from 2003 to 2005, S. flexneri (43.22%) was predominant with S. dysenteriae occupying 41.52%. Indeed, authors have marked the shift of predominant species to S. flexneri by 2005 [23].

Similar type of serogroup changes have been reported in other parts of the world as well. During 1984 in Eastern India, epidemics of shigellosis were caused by multidrug resistant S. dysenteriae serotype 1; in the same region after 18 years in 2002, the epidemics of shigellosis were found to be caused by S. flexneri [24].

In this study, third generation cephalosporins were found to be most sensitive antibiotic (93% of Shigella species were sensitive to ceftriaxone) followed by azithromycin. However, 67% of isolates were resistant to amoxicillin, ciprofloxacin and cotrimoxazole. In comparison to S. flexneri (83% of isolates were resistant), S. sonnei was more sensitive to amoxycillin (all isolates were sensitive). In reverse, 42% of isolates of S. flexneri were sensitive to ciprofloxacin and cotrimoxazole, but all isolates of S. sonnei were resistant to ciprofloxacin and cotrimoxazole. Similar, kind of result have been shown in a study done by Shah et al. in Nepal [21].

In contrast to the developed world, where S. sonnei is common, the occurrence of quinolone resistance is low. For South Asia, S. flexneri continues to be the most common serogroup isolated; antibiotic resistance is emerging including ciprofloxacin resistance [24].

In this study, one of the isolates, S. flexneri was found to be ESBL-producer which accompanied ciprofloxacin resistance along with third generation cephalosporin. Similarly, ESBL has been reported in Shigella species from different parts of the world [10–13].

The ESBL producing Shigella was isolated from 59 months old female child. To our knowledge, this is the first report of ESBL producing Shigella. The isolate is ESBL-producer with MIC >256 mg/L for cefixime and had positive double disk synergy test and combination disk test both. The isolate was sensitive to cefoxitin, eliminating the possibility of AmpC production. However, the lack of generous molecular laboratory facilities didn’t allow genetic characterization, which can be further quest of further study. The emergence of multidrug-resistant (MDR) strains of Shigella is a great concern in South Asia including Nepal [25]. In such a scenario, third-generation cephalosporins are increasingly being used for treating diarrhea where antibiotic is indicated empirically. This, in turn, can lead to the increased prevalence of extended spectrum beta-lactamases (ESBL) producing Shigella sp.

Conclusions

The multi drug resistance is increasing steeply among Shigella spp. accompanying third generation cephalosporin resistance as well in some case. So, systemic monitoring of the species and their antimicrobial susceptibility is becoming crucial to guide therapy.

Abbreviations

AMC: 

amoxycillin–clavulanic acid

ASM: 

American Society for Microbiology

ATCC: 

American type culture collection

BA: 

blood agar

CAZ: 

ceftazidime

CD: 

combination disk

CFU: 

colony forming units

CLSI: 

Clinical and Laboratory Standard Institute

CRO: 

ceftriaxone

D/W: 

distilled water

ESBL: 

extended spectrum β-lactamase

Fig: 

figure

gm: 

gram

Hrs: 

hours

K/A: 

alkaline/acid

LPF: 

low power field

MA: 

MacConkey agar

MDR: 

multi-drug resistant

MHA: 

Mueller Hinton agar

ml: 

millilitre

mm: 

millimetre

No.: 

number

PMN: 

polymorphonuclear neutrophils

SIM: 

sulphide indole motility

TSI: 

triple sugar iron

TUTH: 

Tribhuvan University Teaching Hospital

WHO: 

World Health Organization

µg: 

microgram

µl: 

micro litre

Declarations

Authors' contributions

First authors: SD is primary and corresponding author who designed the study methodology, performed laboratory investigation and prepared the article for submission. JBS and BPR helped to design the study, helped in performing laboratory investigation, performed proof reading of article and made necessary arrangements of reagents. Second authors: BMP, KP and HPK helped for—literature review, design the study and prepare the laboratory protocols and analyzing the impact of the study. SKM and SS helped in designing the study, data entry, analysis and proof reading of article. SK and S Khatiwada helped during filling consent form, sample collection and drafting the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We would like to acknowledge Ph.D. scholars, IOM-Basudha Shrestha and Shovita Shrestha for guiding on Minimum Inhibitory Concentration technique and providing antibiotic powder.

Competing interests

The authors declare they have no competing interests.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Ethics and consent to participate

The ethical approval for study was taken from Institutional Review board, Tribhuvan University Teaching Hospital, IOM before sample collection. The issued letter of IRB can be presented on request.

The written consent was taken from the guardian of the patients in the local language.

Funding

The research was supported by Department of Microbiology, Institute of Medicine, Maharajgunj, Kathmandu.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
National Public Health Laboratory, HIV Reference Unit, Kathmandu, Nepal
(2)
Department of Microbiology, Tribhuvan University Teaching Hospital, Kathmandu, Nepal
(3)
Department of Microbiology, Universal Medical College, Bhairahawa, Nepal

References

  1. World Health Organization. Guidelines for the control of shigellosis including epidemics due to Shigella dysenteriae type 1. Geneva, Switzerland. 2005. http://apps.who.int/iris/bitstream/10665/43252/1/924159330X.pdf. Accessed 5 Nov 2014.
  2. Lima AM, Lima NL, Pinho CNM, Barros EA, Teixeira MJ, Martins MC, Guerrant RL. High frequency of strains multiply resistant to ampicillin, trimethoprim–sulfamethoxazole, streptomycin, chloramphenicol, and tetracycline isolated from patients with shigellosis in Northeastern Brazil during the period 1988 to 1993. Antimicrob Agents Chemother. 1995;39:256–9.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Niyogi SK. Shigellosis. J Microbiol. 2005;43:133–43.PubMedGoogle Scholar
  4. Von Seidlein L, Kim DR, Ali M, Lee H, Wang X, Thiem VD, do Canh G, Chaicumpa W, Agtini MD, Hossain A, Bhutta ZA, Mason C, Sethabutr O, Talukder K, Nair GB, Deen JL, Kotloff K, Clemens JA. Multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med. 2006. doi:10.1371/journal.pmed.0030353.Google Scholar
  5. Tajbakhsh M, García Migura L, Rahbar M, Svendsen CA, Mohammadzadeh M, Zali MR, Aarestrup FM, Hendriksen RS. Antimicrobial resistant Shigella infections from Iran: an overlooked problem? J Antimicrob Chemother. 2012;67:1128–33.View ArticlePubMedGoogle Scholar
  6. Zhang W, Luo Y, Li J, Lin L, Ma Y, Hu C, Jin S, Ran L, Cui S. Wide dissemination of multidrug-resistant Shigella isolates in China. J Antimicrob Chemother. 2011;66:2527–35.View ArticlePubMedGoogle Scholar
  7. Fortineau N, Naas T, Gaillot O, Nordmann P. SHV-type extended-spectrum β-lactamase in a Shigella flexneri clinical isolate. J Antimicrob Chemother. 2001;47:685–8.View ArticlePubMedGoogle Scholar
  8. Pai H, Choi EH, Lee HJ, Hong JY, Jacoby GA. Identification of CTX-M-14 extended-spectrum β-lactamase in clinical isolates of Shigella sonnei, Escherichia coli and Klebsiella pneumonia in Korea. J Clin Microbiol. 2001;39:3747–9.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Radice M, González C, Power P, Vidal MC, Gutkind G, et al. Third-generation cephalosporin resistance in Shigella sonnei Argentina. Emerg Infect Dis. 2001;7:442–3.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Nguyen NT, Ha V, Tran NV, Stabler R, Pham DT, Le TM, van Doorn HR, Cerdeño-Tárraga A, Thomson N, Campbell J, Nguyen VM, Tran TT, Pham MV, Cao TT, Wren B, Farrar J, Baker S. The sudden dominance of blaCTX-M harbouring plasmids in Shigella spp. circulating in Southern Vietnam. PLoS Negl Trop Dis. 2010. doi:10.1371/journal.pntd.0000702.Google Scholar
  11. Acikgoz ZC, Gulay Z, Bicmen M, Gocer S, Gamberzade S. CTX-M-3 extended-spectrum β-lactamase in a Shigella sonnei clinical isolate: first report from Turkey. Scand J Infect Dis. 2003;35:503–5.View ArticlePubMedGoogle Scholar
  12. Bhattacharya D, Bhattacharjee H, Ramanathan T, Sudharma SD, Singhania M, Sugunan AP, Roy S. Third generation cephalosporin resistance in clinical isolate of Shigella sonnei in Andaman & Nicobar Islands India. J Infect Dev Ctries. 2011;5:674–86.PubMedGoogle Scholar
  13. Chander A, Shrestha CD. Prevalence of extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae urinary isolates in a tertiary care hospital in Kathmandu, Nepal. BMC Res Notes. 2013;6:487.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Shrestha S, Amatya R, Dutta R. Prevalence of extended spectrum beta lactamase (ESBL) production in gram negative isolates from pyogenic infection in tertiary care hospital of Eastern Nepal. Nepal Med Coll J. 2011;13:186–9.PubMedGoogle Scholar
  15. Mishra KS, Kattel H, Pokhrel BM. High prevalence of extended-spectrum-beta-lactamase- producing respiratory bacterial pathogens in a Nepalese University Hospital: a vexatious problem. ACCLM. 2015;1:8–14.Google Scholar
  16. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamase: a clinical update. Clin Microbiol Rev. 2005;18:657–86.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Rupp ME, Fey PD. Extended spectrum β-lactamase (ESBL)—producing enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drug. 2003;63:353–65.View ArticleGoogle Scholar
  18. Henry DI. Clinical microbiology procedures handbook. 2nd ed. Washington, DC: ASM Press; 2004.Google Scholar
  19. Sharon ME, Elizabeth EB, Janet FH. Options for treating resistant Shigella species infections in children. J Pediatr Pharmacol Ther. 2008;13:29–43.Google Scholar
  20. Clinical and Laboratory Standards Insitute. Performance standards for antimicrobial susceptebility testing: nineteenth informational supplement M100-S19. Wayne: CLSI; 2009.Google Scholar
  21. Shah BK, Sharma S, Shakya G, Upadhyay BP. Multidrug resistant Vibrio cholera, Salmonella and Shigella from Nepalgunj cholera outbreak and different hospitals of Nepal. Nepal J Biosci. 2012;2:31–9.Google Scholar
  22. Bhattacharya S, Khanal B, Bhattarai NR, Das ML, et al. Prevalence of Shigella species and their antimicrobial resistance pattern in Eastern Nepal. J Health Popul Nutr. 2005;23:339–42.PubMedGoogle Scholar
  23. Kansakar P, Malla S, Ghimire GR. Shigella isolates of Nepal: changes in incidence of Shigella subgroups and trends of antimicrobial susceptibility pattern. KUMJ. 2007;5:32–7.PubMedGoogle Scholar
  24. Taneja N. Changing epidemiology of shigellosis and emergence of ciprofloxacin-resistant Shigella in India. J Clin Microbiol. 2007;45:678–9.View ArticlePubMedGoogle Scholar
  25. Rahman M, Shoma S, Rashid H, Siddique AK, Nair GB, Sack DA. Extended spectrum beta-lactamase mediated third generation cephalosporin resistance in Shigella isolates in Bangladesh. J Antimicrob Chemother. 2004;54:846–7.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s) 2017

Advertisement

BMC Research Notes

ISSN: 1756-0500

Contact us